Daiichi Sankyo will seek to maintain its edge over competitors in precision cancer therapies by pushing ahead with clinical trials of drug candidates being developed using new technology, a top executive has said.
The drugmaker believes its next generation of "antibody drug conjugate" (ADC) medicines that show promise in early stage human testing will help keep the company ahead of the pack, its President and Chief Operating Officer Hiroyuki Okuzawa said on Friday in Tokyo.
"Big pharma companies and Chinese drugmakers are following us, but we will stay ahead of them,” he said.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.